title: Should the concern of myelodysplastic syndrome affect the decision of auto-SCT in lymphoma?
authors.forename: Y-K
authors.initials: YK
authors.lastname: Keung
authors.forename: D
authors.initials: D
authors.lastname: Levitan
authors.forename: K
authors.initials: K
authors.lastname: Zamkoff
authors.forename: D
authors.initials: D
authors.lastname: Hurd
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008224:Lymphoma, Follicular / Q000401:mortality / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000209:etiology*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014182:Transplantation, Autologous / Q000009:adverse effects*